Search research articles

ACERCA DE JoVE

Visión General Liderazgo Blog Centro de Ayuda JoVE

AUTORES

Proceso de Publicación Consejo Editorial Alcance y Políticas Revisión por Pares Preguntas Frecuentes Enviar

BIBLIOTECARIOS

Testimonios Suscripciones Acceso Recursos Consejo Asesor de Bibliotecas Preguntas Frecuentes

INVESTIGACIÓN

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archivo

EDUCACIÓN

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Centro de Recursos para Profesores Sitio de Profesores

Términos y Condiciones de Uso

Política de Privacidad

Videos de Conceptos Relacionados

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

In Vitro Drug Release Testing: Overview, Development and Validation

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por

Same author

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026

Same author

Structural Characteristics of Low-Molecular-Weight Fucoidan and Its Protective Effects on DSS-Induced Colitis and Associated Behavioral Abnormalities by Improving Intestinal Homeostasis.

Journal of agricultural and food chemistry·2026

Same author

Safety, pharmacokinetics, and preliminary efficacy of hetrombopag in pediatric patients with aplastic anemia: A pilot study.

Annals of hematology·2026

Same author

Optimized post-GWAS analysis identifies therapeutic targets for essential thrombocythemia and polycythemia vera.

Communications medicine·2026

Same author

Safety and immunogenicity of a booster dose of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre trial.

Human vaccines & immunotherapeutics·2026

Same author

Cu-Feather-Keratin Nanozymes Enhance the Disease Resistance of <i>Hemerocallis citrina</i> by Inhibiting the Metabolism of <i>Aspergillus awamori</i> and Alleviating Oxidative Stress.

Journal of agricultural and food chemistry·2026

Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Ver todos los artículos relacionados

Search research articles

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Desarrollo de Fármacos

Neil R Cashman^1,2, Steven S Plotkin¹, Scott Napper³

¹University of British Columbia, Vancouver, BC, Canada.

Alzheimer's & dementia : the journal of the Alzheimer's Association

|December 25, 2025

Resumen

Este resumen es generado por máquina.

Una plataforma computacional novedosa permite el desarrollo de anticuerpos y vacunas altamente selectivos dirigidos a proteínas tóxicas mal plegadas implicadas en enfermedades neurodegenerativas como el Alzheimer y el Parkinson.

Palabras clave:

inmunoterapia enfermedades neurodegenerativas anticuerpos vacunas proteínas mal plegadas Alzheimer Parkinson

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Área de la Ciencia:

Neurociencia
Inmunología
Biología Computacional

Sus antecedentes:

Las proteínas tóxicas mal plegadas impulsan enfermedades neurodegenerativas como el Alzheimer (AD), el Parkinson (PD) y el ALS/FTD.
Las estrategias convencionales de inmunización luchan por generar anticuerpos específicos de isoformas de proteínas mal plegadas de la enfermedad.

Objetivo del estudio:

Desarrollar una plataforma para crear inmunoterapias altamente selectivas dirigidas a proteínas tóxicas mal plegadas.
Superar las limitaciones de los métodos convencionales en la generación de anticuerpos específicos de la enfermedad.

Principales métodos:

Utilizada una plataforma computacional para identificar epítopos conformacionales únicos en proteínas tóxicas mal plegadas.
Generados anticuerpos y candidatos a vacunas específicos de mal plegamiento basados en epítopos identificados.
Desarrollado PMN310, un anticuerpo monoclonal humanizado dirigido a oligómeros de Abeta.

Principales resultados:

PMN310 demuestra alta selectividad por oligómeros de Abeta, evitando monómeros y fibrillas, reduciendo así los riesgos como el edema cerebral.
Identificados epítopos para alfa-sinucleína y TDP-43, lo que lleva a anticuerpos candidatos para sinucleinopatías y ALS/FTD.
Epítopos traducidos en vacunas para la terapia dirigida de especies patógenas en modelos preclínicos.

Conclusiones:

La plataforma de ProMIS supera los problemas de especificidad de las inmunizaciones tradicionales.
Permite el desarrollo de inmunoterapias pasivas y activas selectivas para enfermedades neurodegenerativas.